MPLT
NASDAQMapLight Therapeutics Inc.
News25/Ratings12
Price$12.51+0.92 (+7.94%)
01:30 PM07:45 PM
News · 26 weeks94-22%
2026-03-012026-08-23
Mix4790d
- Insider24(51%)
- SEC Filings12(26%)
- Analyst5(11%)
- Other4(9%)
- Leadership1(2%)
- Offering1(2%)
Latest news
25 items- INSIDERChief Discovery Officer Kreitzer Anatol was granted 6,020 units of Voting Common Stock, increasing direct ownership by 3% to 180,926 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERCAO and Interim CFO Gillis Jonathan was granted 8,242 units of Voting Common Stock, increasing direct ownership by 6% to 152,482 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERChief Executive Officer Kroeger Christopher A. was granted 23,145 units of Voting Common Stock, increasing direct ownership by 2% to 1,269,600 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERGeneral Counsel Hanson Kristopher was granted 7,730 units of Voting Common Stock, increasing direct ownership by 5% to 153,553 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERChief Medical Officer Foff Erin Pennock was granted 13,360 units of Voting Common Stock, increasing direct ownership by 4% to 312,261 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERChief Scientific Officer Lillie James Woodruff was granted 7,730 units of Voting Common Stock, increasing direct ownership by 4% to 210,110 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERLarge owner Catalyst4, Inc. bought $50,072,000 worth of Voting Common Stock (4,400,000 units at $11.38) (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- SECSEC Form 10-Q filed by MapLight Therapeutics Inc.10-Q - MapLight Therapeutics, Inc. (0001770069) (Filer)
- SECMapLight Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure8-K - MapLight Therapeutics, Inc. (0001770069) (Filer)
- PRMapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateReported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial Continued advancement of ML-007C-MA in ADP, with enrollment ongoing in the Phase 2 VISTA trial and topline results expected in the second half of 2027 Reported Phase 2 IRIS results for ML-004 in autism spectrum disorder, with clinically meaningful improvements in irritability observed in a prespecified adolescent subgroup Primarily focusing resources on the advancement of ML-007C-MA Ended the quarter with $351.3 million in cash, cash equivalents and investments, which, together with the Company’s recent $150 million privat
- PRMapLight Therapeutics Announces $150 Million Private Placement FinancingSAN FRANCISCO and BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (NASDAQ:MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the "PIPE") for gross proceeds of approximately $150 million, before deducting placement agent fees and estimated offering expenses. The financing is being led by new and existing institutional investors. In the PIPE, MapLight is selling an aggregate of 9,197,887 shares of it
- ANALYSTMapLight Therapeutics downgraded by UBS with a new price targetUBS downgraded MapLight Therapeutics from Buy to Neutral and set a new price target of $13.00
- INSIDERChief Scientific Officer Lillie James Woodruff sold $276,908 worth of Voting Common Stock (22,082 units at $12.54) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 202,380 units (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- SECSEC Form 144 filed by MapLight Therapeutics Inc.144 - MapLight Therapeutics, Inc. (0001770069) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by MapLight Therapeutics Inc.SCHEDULE 13D/A - MapLight Therapeutics, Inc. (0001770069) (Subject)
- SECSEC Form 144 filed by MapLight Therapeutics Inc.144 - MapLight Therapeutics, Inc. (0001770069) (Subject)
- INSIDERLarge owner Catalyst4, Inc. bought $15,314,794 worth of Voting Common Stock (1,209,225 units at $12.66) (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERDirector Cox Troy bought $148,702 worth of Voting Common Stock (15,620 units at $9.52) (SEC Form 4)4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- ANALYSTMapLight Therapeutics downgraded by Morgan Stanley with a new price targetMorgan Stanley downgraded MapLight Therapeutics from Overweight to Equal-Weight and set a new price target of $21.00
- SECMapLight Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - MapLight Therapeutics, Inc. (0001770069) (Filer)
- PRMapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in SchizophreniaThe trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID dose demonstrating a statistically significant improvement in PANSS total score compared to placebo at Week 5 with an effect size of 0.37 (LS mean difference vs PBO -4.5, p=0.015) Cognitive performance was improved (ES=0.51, p=0.041) in those with baseline cognitive impairment on a prespecified secondary endpoint 210/3 mg BID dose also achieved significant separation on key secondary endpoints, including CGI-S (ES=0.48, p=0.002) and PANSS Positive Marder Factor (ES=0.39, p=0.012) ML-007C-MA was generally well tolerated at both doses studied, with no serious or drug-related severe advers
- ANALYSTBMO Capital Markets initiated coverage on MapLight Therapeutics with a new price targetBMO Capital Markets initiated coverage of MapLight Therapeutics with a rating of Outperform and set a new price target of $46.00
- INSIDERChief Discovery Officer Kreitzer Anatol sold $1,345,894 worth of Voting Common Stock (36,284 units at $37.09) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 174,906 units (SEC Form 4) to cover withholding tax4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERCAO and Interim CFO Gillis Jonathan sold $1,372,668 worth of Voting Common Stock (36,979 units at $37.12) as part of a pre-agreed trading plan, decreasing direct ownership by 20% to 144,240 units (SEC Form 4) to satisfy tax liability4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
- INSIDERChief Executive Officer Kroeger Christopher A. sold $5,443,722 worth of Voting Common Stock (147,639 units at $36.87), decreasing direct ownership by 11% to 1,246,455 units (SEC Form 4) to satisfy withholding obligation4 - MapLight Therapeutics, Inc. (0001770069) (Issuer)
MPLT FAQ
6 questionsWhere does MPLT stock trade?
MapLight Therapeutics Inc. (MPLT) is listed on NASDAQ.What sector and industry is MPLT in?
MapLight Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did MapLight Therapeutics Inc. go public?
MapLight Therapeutics Inc. (MPLT) completed its IPO in 2025.What are analysts saying about MPLT?
MapLight Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Neutral with a $1300.00 price target on 2026-08-10. Recent price targets range from $1300.00 to $4800.00.What companies are similar to MPLT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MPLT side-by-side with any of them on Quantisnow.How can I track MPLT on Quantisnow?
Quantisnow aggregates MapLight Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MPLT to receive live email and push alerts on every new disclosure.